Summary: Research from Uppsala University shows that patient expectations—the placebo effect—interact with dopamine signaling to shape how well social anxiety and depressive symptoms respond to SSRI treatment. Patients who believed the medication would help were nearly four times more likely to show improvement than those given a neutral or deceptive expectation, even though both groups received the same drug and dose.
Source: Uppsala University
How dopamine and the placebo effect influence SSRI outcomes for social anxiety
A controlled clinical study indicates that expectations about treatment — the placebo effect — play a major role in whether people with social anxiety benefit from selective serotonin reuptake inhibitors (SSRIs). The trial found that the positive clinical response to the SSRI escitalopram was almost four times greater in participants who were explicitly informed that the medication was effective compared with those who were told it was an “active placebo” and not expected to reduce anxiety. Crucially, brain imaging revealed that this difference in outcome was linked more to changes in dopamine transporter availability than to serotonin transporter blockade.
SSRIs are widely used to treat depression and anxiety by inhibiting the serotonin transporter, increasing serotonin availability in the brain. However, this study suggests that blocking serotonin transporters alone may not be sufficient for clinical improvement in social anxiety disorder (SAD). Instead, psychological factors that alter dopaminergic activity appear to amplify or enable the therapeutic effects of SSRI treatment.
All participants received the same therapeutic dose of escitalopram for nine weeks. The trial randomized 27 individuals with diagnosed social anxiety disorder into two groups: one received accurate, positive information about the drug’s efficacy (overt treatment), while the other received a deceptive cover story describing the pill as an active placebo that produces side effects but is not intended to relieve anxiety (covert treatment). Despite identical pharmacological exposure, the groups showed markedly different clinical outcomes.
“The results showed that almost four times as many patients responded to the treatment when correct information about the drug was given. This is consistent with previous research showing that expectations affect treatment outcome,” says researcher Olof Hjorth. Objective brain measures supported this clinical difference: positron emission tomography (PET) scans revealed that SERT (serotonin transporter) occupancy by escitalopram was high and comparable in both groups, with roughly 80% blockade after treatment.
Because serotonin transporter inhibition was similar across participants regardless of expectation or symptom change, the investigators looked for other neurochemical explanations. They measured dopamine transporter (DAT) availability using PET tracers sensitive to DAT and found opposing patterns between groups. Participants who received accurate information about the medication showed a reduction in DAT availability in regions of the striatum and related structures, while those given the cover story showed relative increases in DAT availability. These regional DAT changes correlated with symptom improvement, suggesting that dopaminergic mechanisms linked to reward and motivation contributed to therapeutic response.
Professor Tomas Furmark, who led the study, explains: “The results indicate that positive expectations arising in the relationship between doctor and patient affect dopamine and enhance the effect of SSRI treatment.” One plausible interpretation is that positive expectations enhance dopamine release in reward pathways, which in turn alters transporter availability and facilitates clinical improvement when combined with SSRI pharmacology.
About this psychopharmacology research news
Author: Press Office
Source: Uppsala University
Contact: Press Office – Uppsala University
Image: The image is in the public domain
Original Research: Open access. “Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial” by Olof R. Hjorth et al., published in Translational Psychiatry.
Abstract
Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial
It remains debated whether SSRIs outperform placebo in affective disorders and how they deliver clinical benefit. Beyond serotonin transporter blockade, changes in dopamine signaling and psychological factors may play important roles. In this randomized trial of individuals with social anxiety disorder, researchers manipulated verbally induced expectancies—an essential element of placebo responses—to examine how these expectations influence brain monoamine transporters and symptom change during SSRI therapy.
Twenty-seven participants (17 men, 10 women) underwent nine weeks of escitalopram 20 mg, randomized to overt (accurate information) or covert (deceptive description as an active placebo) treatment. Before and after therapy, patients received PET scans with [11C]DASB and [11C]PE2I to assess serotonin (SERT) and dopamine (DAT) transporter binding. Social anxiety symptoms were measured with the Liebowitz Social Anxiety Scale. Overt treatment produced nearly a fourfold higher response rate than covert treatment.
PET findings showed high, equivalent SERT occupancy across groups that was unrelated to symptom change. By contrast, DAT binding decreased in right putamen and pallidum and left thalamus after overt treatment, whereas DAT increased with covert treatment, producing significant group differences. Changes in DAT binding correlated negatively with symptom reduction. These results support a model in which anxiolytic effects of SSRIs depend on psychological factors that engage dopaminergic neurotransmission, while serotonin transporter blockade alone may be insufficient for clinical response in social anxiety disorder.